

Elliott M Antman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2782070/publications.pdf>

Version: 2024-02-01

159
papers

13,730
citations

61984

43
h-index

20961

115
g-index

165
all docs

165
docs citations

165
times ranked

13845
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal, 2022, 247, 24-32.	2.7	6
2	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	5.9	38
3	The inclusion of augmented intelligence in medicine: A framework for successful implementation. Cell Reports Medicine, 2022, 3, 100485.	6.5	27
4	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. JAMA Network Open, 2022, 5, e2147375.	5.9	30
5	Ideal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2022, 9, 814610.	2.4	5
6	Sodium and Health: Old Myths and a Controversy Based on Denial. Current Nutrition Reports, 2022, 11, 172-184.	4.3	32
7	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 695-706.	3.0	5
8	A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 12-20.	2.5	5
9	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58,634 patients across four randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f40-f49.	3.0	13
10	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	3.4	22
11	An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. Journal of Clinical and Translational Science, 2021, 5, e137.	0.6	0
12	Comprehensive characterization of protein-protein interactions perturbed by disease mutations. Nature Genetics, 2021, 53, 342-353.	21.4	109
13	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
14	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13,065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation, 2021, 143, 673-684.	1.6	10
15	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2021, 42, 1698-1706.	2.2	27
16	The path to universality. European Journal of Heart Failure, 2021, 23, 381-383.	7.1	2
17	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 77, 1197-1207.	2.8	29
18	Data from Digital Health Devices Informs Ideal Cardiovascular Health. Journal of Personalized Medicine, 2021, 11, 189.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 294-300.	1.5	5
20	Obesity and Ideal Cardiovascular Health: Results from the My Research Legacy Study. <i>Obesity</i> , 2021, 1, 36-48.	0.8	0
21	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	27.0	145
22	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. <i>American Heart Journal</i> , 2021, 235, 132-139.	2.7	3
23	Ideal Cardiovascular Health in Former Smokers. <i>Journal of Clinical Medicine</i> , 2021, 10, 2450.	2.4	5
24	A precision medicine approach to sex-based differences in ideal cardiovascular health. <i>Scientific Reports</i> , 2021, 11, 14848.	3.3	3
25	Digital health device measured sleep duration and ideal cardiovascular health: an observational study. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 497.	1.7	2
26	Exploring patient experiences coping with using multiple medications: a qualitative interview study. <i>BMJ Open</i> , 2021, 11, e046860.	1.9	3
27	Pooling Data From Individual Clinical Trials in the COVID-19 Era. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 543.	7.4	63
28	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	2.8	25
29	Managing Stable Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1468-1470.	27.0	36
30	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020, 304, 185-191.	1.7	25
31	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. <i>International Journal of Cardiology</i> , 2020, 317, 159-166.	1.7	2
32	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019, 74, 597-605.	2.7	16
33	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019, 140, 1792-1801.	1.6	22
34	Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction—Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0222061.	2.5	8
35	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579.	7.1	44
36	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022.	2.8	54

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1518-1527.	2.2	67
38	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771.	1.6	99
39	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , 2019, 21, 306-312.	1.7	6
40	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1541-1550.	2.2	88
41	Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing. <i>NAM Perspectives</i> , 2019, 2019, .	2.9	4
42	The Aspirin-NSAID Interaction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1752-1754.	2.8	10
43	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018, 257, 102-107.	1.7	18
44	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008.	3.4	18
45	The Introduction and Clinical Use of Cardiac-Specific Troponin Assays. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 31-33.	4.7	6
46	Improving care at the population and individual level: lessons from SWEDEHEART. <i>European Heart Journal</i> , 2018, 39, 3777-3779.	2.2	5
47	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1466-1475.	2.8	10
48	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	2.2	28
49	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973.	1.6	32
50	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw565.	2.2	37
51	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	139
52	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
53	Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. <i>Circulation</i> , 2017, 135, 2062-2072.	1.6	28
54	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382.	2.8	111

#	ARTICLE	IF	CITATIONS
55	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	3.7	21
56	NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nature Reviews Drug Discovery, 2017, 16, 663-664.	46.4	2
57	First experience with edoxaban and atrial fibrillation ablation â€“ Insights from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2017, 244, 192-195.	1.7	19
58	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	3.7	30
59	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	53
60	Standards for Clinical Research. Circulation, 2016, 133, 823-825.	1.6	10
61	The Prognostic Significance of Cardiac Structure andÂFunction in Atrial Fibrillation: The ENGAGE AFâ€TIMI 48 Echocardiographic Substudy. Journal of the American Society of Echocardiography, 2016, 29, 537-544.	2.8	29
62	Edoxaban Versus Warfarin in AtrialÂFibrillation Patients at Risk of Falling. Journal of the American College of Cardiology, 2016, 68, 1169-1178.	2.8	133
63	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 999.	6.1	64
64	Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction. Circulation, 2016, 134, 378-391.	1.6	148
65	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	2.0	83
66	Management of Nonâ€ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2016, 316, 1045.	7.4	0
67	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AFâ€TIMI48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	93
68	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation, 2016, 134, 24-36.	1.6	234
69	Precision medicine in cardiology. Nature Reviews Cardiology, 2016, 13, 591-602.	13.7	183
70	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. American Journal of Medicine, 2016, 129, 850-857.e2.	1.5	58
71	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillationâ€Thrombolysis in Myocardial Infarction 48 (ENGAGE AFâ€TIMI 48) trial. American Heart Journal. 2016. 172. 144-151.	2.7	13
72	Improving Quality of Cardiac Care: A Global Mandate. Revista Espanola De Cardiologia (English Ed), 2015, 68, 924-927.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. European Heart Journal, 2015, 36, 1470-1477.	2.2	47
74	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2288-2295.	13.7	335
75	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. JAMA Internal Medicine, 2015, 175, 207.	5.1	72
76	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. American Heart Journal, 2015, 170, 1140-1150.	2.7	26
77	Saving and Improving Lives in the Information Age. Circulation, 2015, 131, 2238-2242.	1.6	3
78	Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers. JACC: Heart Failure, 2015, 3, 180-188.	4.1	137
79	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2280-2287.	13.7	153
80	Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate. Circulation, 2015, 131, 82-90.	1.6	240
81	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. European Heart Journal, 2014, 35, 1457-1465.	2.2	174
82	Reducing the Risk of Heart Attack and Stroke. Circulation, 2014, 130, e48-50.	1.6	0
83	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	2.0	46
84	Clinical Practice Guidelines for Chronic Cardiovascular Disorders: A Roadmap for the Future. JAMA - Journal of the American Medical Association, 2014, 311, 1195.	7.4	10
85	Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation. Journal of the American College of Cardiology, 2014, 64, 576-584.	2.8	39
86	Clinical Research and the Development of Medical Therapeutics. Circulation Journal, 2014, 78, 1267-1271.	1.6	3
87	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	27.0	4,215
88	Concomitant Administration of Clopidogrel With Statins or Calcium-Channel Blockers. JACC: Cardiovascular Interventions, 2013, 6, 1275-1281.	2.9	37
89	Transforming Clinical Trials in Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1743.	7.4	39
90	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2012, 4, 367-383.	6.6	40

#	ARTICLE	IF	CITATIONS
91	Evidence and Education. Circulation, 2011, 123, 681-685.	1.6	5
92	Response to Letter Regarding Article, "Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38". Circulation, 2010, 122, .	1.6	1
93	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective Anticoagulation with factor xA next Generation in Atrial Fibrillation "Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF"TIMI 48). American Heart Journal, 2010, 160, 635-641.e2.	2.7	439
94	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, The, 2009, 374, 989-997.	13.7	650
95	The Specialty of Emergency Medicine: Needed Now More Than Ever Before. Annals of Emergency Medicine, 2008, 52, 317-319.	0.6	1
96	Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 51, 2028-2033.	2.8	314
97	Use of Nonsteroidal Antiinflammatory Drugs. Circulation, 2007, 115, 1634-1642.	1.6	698
98	Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat. Circulation, 2005, 112, .	1.6	5
99	Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation, 2005, 112, 759-770.	1.6	237
100	Pharmacoinvasive Therapy. Circulation, 2004, 109, 2480-2486.	1.6	48
101	Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST"segment elevation myocardial infarction: Appropriate interpretation of the guidelines. American Heart Journal, 2003, 146, S18-S22.	2.7	29
102	Should Evidence-Based Proof of Efficacy as Defined for a Specific Therapeutic Agent be Extrapolated to Encompass a Therapeutic Class of Agents?. Circulation, 2003, 108, 2604-2607.	1.6	18
103	Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction. Circulation, 2002, 105, 1642-1649.	1.6	228
104	Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial. American Heart Journal, 2002, 143, 229-234.	2.7	62
105	Clinical Trials in Cardiovascular Medicine. Circulation, 2001, 103, E101-4.	1.6	5
106	The Search for Replacements for Unfractionated Heparin. Circulation, 2001, 103, 2310-2314.	1.6	70
107	Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. Circulation, 2001, 103, 2550-2554.	1.6	440
108	Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clinical Chemistry, 2000, 46, 453-460.	3.2	113

#	ARTICLE	IF	CITATIONS
109	TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. <i>Circulation</i> , 2000, 102, 2031-2037.	1.6	1,302
110	The Long-term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1999, 3, 96-99.	1.0	0
111	Pathogenesis and pathology of coronary heart disease syndromes. , 1999, 8, 167-189.		15
112	The role of cardiac Troponinâ€ (cTnI) in risk stratification of patients with unstable coronary artery disease. <i>Clinical Cardiology</i> , 1999, 22, 13-16.	1.8	21
113	Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 1999, 131, 235.	3.9	0
114	Pharmacological Therapy of Cardiac Arrhythmias. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 6, 211-238.	2.1	0
115	The Thrombin Hypothesis: Dead or Alive?. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, S137-S141.	2.1	0
116	Noninvasive Cardiac Imaging in Chest Pain Syndromes. , 1998, 6, 239-252.		0
117	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 321-323.	2.1	0
118	Long-Term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997, 1, 40-43.	1.0	1
119	The role of magnesium therapy in acute myocardial infarction. <i>Clinical Cardiology</i> , 1996, 19, 841-844.	1.8	8
120	Hirudin in Acute Myocardial Infarction. <i>Circulation</i> , 1996, 94, 911-921.	1.6	393
121	Atrial Fibrillation and Flutter: Maintaining Stability of Sinus Rhythm Versus Ventricular Rate Control. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 962-971.	1.7	18
122	Magnesium in Acute MI. <i>Circulation</i> , 1995, 92, 2367-2372.	1.6	55
123	A Neural Network System for Detection of Atrial Fibrillation in Ambulatory Electrocardiograms. <i>Journal of Cardiovascular Electrophysiology</i> , 1994, 5, 602-608.	1.7	16
124	Current Diagnosis and Prescription for Marfan Syndrome: When to Operate. <i>Journal of Cardiac Surgery</i> , 1994, 9, 174-176.	0.7	16
125	Documented Symptomatic Bradycardia and Symptom Relief in Patients Receiving Permanent Pacemakers: An Evaluation of the Joint ACC/AHA Pacing Guidelines. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988, 11, 1098-1104.	1.2	6
126	Pacemaker-Mediated Tachycardia Initiated by Coincident P-Wave Undersensing and Ventricular Blanking Period. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1985, 8, 436-439.	1.2	7

#	ARTICLE	IF	CITATIONS
127	Nifedipine in the Treatment of Cardiovascular Disease. Pharmacotherapy, 1981, 1, 78-90.	2.6	11
128	Non-CRT Pacing in the Failing Heart: Limiting Ventricular Pacing and Searching for Alternate Pacing Sites. , 0, , 248-283.		0
129	ST-Elevation Myocardial Infarction. , 0, , 46-90.		8
130	Antiplatelet Therapy in Peripheral Arterial Disease. , 0, , 196-214.		0
131	Laboratory Assessment of Platelet Function and the Effects of Antiplatelet Agents. , 0, , 15-29.		0
132	Programming CRT Devices. , 0, , 180-219.		1
133	Author Disclosure Table. , 0, , 291-296.		0
134	Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease. , 0, , 1-14.		0
135	Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation. , 0, , 143-163.		0
136	Antiplatelet Therapy in ST-Elevation Myocardial Infarction. , 0, , 164-177.		0
137	Antiplatelet Therapy in Chronic Coronary Artery Disease. , 0, , 178-195.		0
138	Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases. , 0, , 215-229.		0
139	Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits. , 0, , 231-250.		0
140	Management of Antiplatelet Therapy for Non-Cardiac Surgery. , 0, , 251-264.		0
141	Antiplatelet Therapy and Coronary Stents. , 0, , 265-279.		0
142	Cyclooxygenase Inhibitors. , 0, , 31-46.		0
143	Aspirin Response Variability and Resistance. , 0, , 47-58.		0
144	P2Y12 Inhibitors: Thienopyridines and Direct Oral Inhibitors. , 0, , 59-76.		0

#	ARTICLE	IF	CITATIONS
145	Thienopyridine Response Variability and Resistance. , 0, , 77-93.		0
146	Pharmacology of Intravenous Glycoprotein IIb/IIIa Antagonists. , 0, , 95-110.		0
147	Intravenous P2Y12 Inhibitors. , 0, , 111-124.		0
148	Antiplatelet Effects of Thrombin Inhibitors and Fibrinolytic Agents. , 0, , 125-142.		0
149	Troubleshooting CRT Devices and Clinical Outcomes. , 0, , 220-247.		0
150	Implantation of a CRT Device. , 0, , 156-179.		0
151	Author Disclosure Table. , 0, , 349-353.		0
152	Non-CRT Pacing in the Failing Heart: Cardiac Contractility Modulation (CCM). , 0, , 284-296.		0
153	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction. , 0, , 1-30.		0
154	Pathobiology of Left Ventricular Dyssynchrony and Resynchronization. , 0, , 31-56.		0
155	Clinical Trials and Response to CRT. , 0, , 130-155.		2
156	Future Directions in Pacing to Support the Failing Heart. , 0, , 319-335.		0
157	Electrical Assessment of the Failing Heart. , 0, , 57-91.		0
158	Clinical Outcomes and Chronic Management of Device Patients. , 0, , 297-318.		0
159	Mechanical Assessment of the Failing Heart. , 0, , 92-129.		0